SCHEMBL6397828

SCHEMBL6397828

O=C(NCCCCl)Nc1ccnc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HTT P42858 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
PLK4 O00444 1/20 0.54
CHEK1 O14757 1/20 0.54
PDPK1 O15530 1/20 0.54
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
CHEK2 O96017 1/20 0.54
CDK1 P06493 1/20 0.54
PIM1 P11309 1/20 0.54
RPS6KB1 P23443 1/20 0.54
CDK2 P24941 1/20 0.54
FLT4 P35916 1/20 0.54
KDR P35968 1/20 0.54
CSNK1D P48730 1/20 0.54
CDK8 P49336 1/20 0.54
CLK2 P49760 1/20 0.54
GSK3A P49840 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859948 0.93 ALDH1A1 (0.57) ALDH1A1HTTSMN1; SMN2LMNAPLK4
SCHEMBL27579461 0.82 PLK4 (0.73) ALDH1A1HTTSMN1; SMN2LMNAPLK4
SCHEMBL28270221 0.81 HTT (0.81) ALDH1A1HTTSMN1; SMN2LMNAPLK4
SCHEMBL4863981 0.81 PLK4 (0.56) ALDH1A1HTTSMN1; SMN2LMNAPLK4
SCHEMBL4859824 0.80 HTT (0.57) ALDH1A1HTTSMN1; SMN2HTR2CKDM4E
Hydrochloric Acid SCHEMBL4860155 0.80 PLK4 (0.55) ALDH1A1HTTSMN1; SMN2LMNAPLK4
SCHEMBL5527306 0.78 HRH3 (0.68) KDM4EMEN1KMT2A
SCHEMBL5735461 0.77 MAPT (0.57) HTR2CMEN1KMT2A
SCHEMBL7372365 0.76 PABPC1 (0.61) ALDH1A1HTTSMN1; SMN2LMNAPLK4
SCHEMBL3807061 0.76 HTR2C (0.73) ALDH1A1PLK4CHEK1PDPK1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379523-B1 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2005-07-27 EP disclosed
US-20040242564-A1 1,2,3,4-tetrahydroisoquinolines derivatives VELKER JORG (DE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242564-A1 1,2,3,4-tetrahydroisoquinolines derivatives ADRA2C, ADRA1D, ADRB3 ALDH1A1 1364/4885HTT 684/4885SMN1; SMN2 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.